Detalhe da pesquisa
1.
CLDN18.2 BiTE Engages Effector and Regulatory T Cells for Antitumor Immune Response in Preclinical Models of Pancreatic Cancer.
Gastroenterology
; 165(5): 1219-1232, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37507075
2.
Harnessing T cells to fight cancer with BiTE® antibody constructs--past developments and future directions.
Immunol Rev
; 270(1): 193-208, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26864113
3.
Characterization and root cause analysis of immunogenicity to pasotuxizumab (AMG 212), a prostate-specific membrane antigen-targeting bispecific T-cell engager therapy.
Front Immunol
; 14: 1261070, 2023.
Artigo
em Inglês
| MEDLINE | ID: mdl-37942314
4.
Mesothelin/CD3 half-life extended bispecific T-cell engager molecule shows specific tumor uptake and distributes to mesothelin and CD3 expressing tissues.
J Nucl Med
; 2021 Apr 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-33931466
5.
Pasotuxizumab, a BiTE® immune therapy for castration-resistant prostate cancer: Phase I, dose-escalation study findings.
Immunotherapy
; 13(2): 125-141, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-33172323
6.
The Biodistribution of a CD3 and EpCAM Bispecific T-Cell Engager Is Driven by the CD3 Arm.
J Nucl Med
; 61(11): 1594-1601, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32284393
7.
A multicenter phase 1 study of solitomab (MT110, AMG 110), a bispecific EpCAM/CD3 T-cell engager (BiTE®) antibody construct, in patients with refractory solid tumors.
Oncoimmunology
; 7(8): e1450710, 2018.
Artigo
em Inglês
| MEDLINE | ID: mdl-30221040
8.
Molecular Imaging of Radiolabeled Bispecific T-Cell Engager 89Zr-AMG211 Targeting CEA-Positive Tumors.
Clin Cancer Res
; 24(20): 4988-4996, 2018 10 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-29980531
9.
Immune checkpoints PVR and PVRL2 are prognostic markers in AML and their blockade represents a new therapeutic option.
Oncogene
; 37(39): 5269-5280, 2018 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29855615
10.
Biodistribution and PET Imaging of Labeled Bispecific T Cell-Engaging Antibody Targeting EpCAM.
J Nucl Med
; 57(5): 812-7, 2016 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-26848172